tirzepatide on shortage list FDA Removes from Tirzepatide Shortage Resolved? FDA Says

Cardiovascular disease (CVD) is the main cause of death and disability among people with type 2 diabetes.[2] Adults with type 2 diabetes are two to four times more likely to develop CVD than adults without diabetes.[3] The FDA's decision on semaglutide is based on results from the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which examined the cardiovascular safety of adding Ozempic or placebo to standard-of-care in adults with type 2 diabetes and established cardiovascular disease

All-inclusive, bilingual.

Semaglutide shows potential kidney-protective benefits beyond weight loss, with studies indicating improved kidney function markers in certain patient populations

Discover trends in diabetes care, weight-loss demand, pricing, and generics.